Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1970 1
1975 1
1976 1
1983 2
1996 1
1999 1
2004 2
2005 1
2006 2
2007 4
2009 1
2010 3
2011 6
2012 14
2013 8
2014 13
2015 12
2016 8
2017 9
2018 12
2019 9
2020 14
2021 24
2022 31
2023 18
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Ramathasan
Page 1
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ; VISION Investigators. Sartor O, et al. N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23. N Engl J Med. 2021. PMID: 34161051 Free PMC article. Clinical Trial.
Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies.
Privé BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW, van Lith SAM, Mehra N, Nagarajah J, Heskamp S, Westdorp H. Privé BM, et al. Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):1906-1918. doi: 10.1007/s00259-023-06144-0. Epub 2023 Feb 23. Eur J Nucl Med Mol Imaging. 2023. PMID: 36813980 Free PMC article. Review.
PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.
Uijen MJM, Derks YHW, Merkx RIJ, Schilham MGM, Roosen J, Privé BM, van Lith SAM, van Herpen CML, Gotthardt M, Heskamp S, van Gemert WAM, Nagarajah J. Uijen MJM, et al. Eur J Nucl Med Mol Imaging. 2021 Dec;48(13):4350-4368. doi: 10.1007/s00259-021-05433-w. Epub 2021 Jun 12. Eur J Nucl Med Mol Imaging. 2021. PMID: 34120192 Free PMC article. Review.
Tubotympanic cholesteatoma.
Nagarajah D, Md Daud MK, Salehuddin NS, Nik Othman NA. Nagarajah D, et al. Malays Fam Physician. 2021 Sep 8;16(3):123-125. doi: 10.51866/cr1136. eCollection 2021 Nov 30. Malays Fam Physician. 2021. PMID: 34938404 Free PMC article.
Personalia.
Burchert W. Burchert W. Nuklearmedizin. 2018 Feb;57(1):N6-N8. doi: 10.1055/s-0038-1638277. Epub 2018 Mar 1. Nuklearmedizin. 2018. PMID: 29536492 German. No abstract available.
Iodine Symporter Targeting with 124I/131I Theranostics.
Nagarajah J, Janssen M, Hetkamp P, Jentzen W. Nagarajah J, et al. J Nucl Med. 2017 Sep;58(Suppl 2):34S-38S. doi: 10.2967/jnumed.116.186866. J Nucl Med. 2017. PMID: 28864610 Free article. Review.
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.
Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. Fizazi K, et al. Lancet Oncol. 2023 Jun;24(6):597-610. doi: 10.1016/S1470-2045(23)00158-4. Lancet Oncol. 2023. PMID: 37269841 Clinical Trial.
178 results